CFTR and lung disorder: With expanding use of highly effective CFTR modulatory therapy among younger patients with CF, including recent approval for elexacaftor/tezacaftor/ivacaftor for ages two and above, the natural history of the onset and progression of lung disease in young children is likely to change.